BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell?

BrightSpring Health Services' Q2 revenue rose 23% year over year to $3.9 billion and adjusted EBITDA increased 44% to $206 million, lifting EBITDA margin 80bps to 5.3%; shares are up 54.6% YTD. Management forecasts 2026 revenue of $15.1-$15.425 billion (+17%-19.5%) and adjusted EBITDA of $820-$845 million (+32.8%-36.8%), driven by 30% Specialty/Infusion revenue growth and strong infusion volumes. Risks include a roughly 600bp CID-related revenue headwind, a $55 million gross-profit impact, and an expected $200 million 2026 IRA-related revenue reduction in Home and Community Pharmacy, while the stock trades at a premium 22.06x forward P/E.

Analysis

BTSG’s investable edge is not simply growth but mix: limited-distribution access and infusion intake create a higher-switching-cost channel than conventional home pharmacy. If specialty scripts continue converting into recurring infusion and adherence services, gross-profit dollars can compound faster than revenue and support further multiple durability. The counterweight is that LDD economics are contract- and manufacturer-concentrated; a small number of non-renewals could materially impair growth despite apparently broad platform momentum.

The key earnings-quality question is whether margin gains survive the unfavorable mix shift already embedded in guidance. The disclosed chronic-inflammatory gross-profit drag is roughly 6%-7% of guided annual EBITDA at the midpoint, so execution requires specialty/infusion contribution to exceed a meaningful offset rather than merely sustain recent volume growth. Also reconcile segment EBITDA with consolidated EBITDA in the next filing: the gap can reflect corporate costs, eliminations, or adjustments, and determines how much of reported operating leverage is scalable.

At a substantial valuation premium to OPCH and ADUS, BTSG now trades as an earnings-revision vehicle rather than a simple healthcare-services beta. Over the next 1-3 months, confirmation of guidance through script growth, infusion starts, and stable gross-profit per script can support another leg higher; any reduction in EBITDA guidance or incremental CID pricing pressure would likely cause outsized multiple compression. The contrarian view is that the market may be underpricing both the durability of LDD network access and the probability that IRA-related revenue exits improve low-quality revenue mix; the latter is bullish only if gross profit and cash conversion remain intact.

OPCH is the clearest competitive read-through, but its lower valuation means BTSG share gains do not automatically justify a directional short in OPCH. MCO has no actionable linkage beyond immaterial ratings-agency exposure; credit-rating improvement is a financing optionality signal, not an earnings driver.

Key Decisions for Investors

• Maintain or initiate a measured BTSG long only on post-results weakness or after confirmation that full-year EBITDA guidance is maintained; use a 6-12 month horizon. Thesis requires specialty/infusion gross profit to offset the CID drag, with a 15%-20% upside case if estimates continue to revise higher versus meaningful downside from de-rating if guidance slips.
• Set a hard monitoring trigger for BTSG: reduce exposure on an EBITDA-guide cut, evidence of LDD contract losses, or a second consecutive quarter of weaker gross-profit conversion despite volume growth. Revenue alone is insufficient because the policy-related headwinds are concentrated in profitability.
• Do not chase a long BTSG/short OPCH pair at current relative valuations. Instead, watch for BTSG’s premium to widen further without upward EBITDA revisions; that would create a more attractive 3-6 month mean-reversion pair, long OPCH versus short BTSG, subject to confirming comparable infusion mix and reimbursement exposure.
• Track quarterly Home and Community Pharmacy gross profit and operating cash flow, not just its revenue decline. If customer exits stabilize margin and working-capital conversion, the segment becomes a hidden upside catalyst over 6-18 months; if gross profit falls with revenue, it invalidates the mix-improvement thesis.